Baroldi Joseph, Executive Vice President and Chief Business Officer, has demonstrated a clear selling bias in his recent insider trading activity, as evidenced by SEC Form 4 filings. Over the course of 52 transactions, all involving Ionis Pharmaceuticals (IONS), Joseph has sold shares totaling $5,831,666.67, significantly outweighing his purchases of $1,526,281.24. This trend is particularly pronounced in his recent trades, where he executed 11 sales between January 2025 and March 2026, with no corresponding buys. Notable transactions include a sale of $1,020,210 on October 2, 2025, and another of $742,838.29 on September 9, 2025, both accompanied by smaller sales and exercises of derivative securities. More recently, Joseph sold shares worth $325,058.56 on March 3, 2026, and $439,364.10 on January 30, 2026, further solidifying his consistent divestment pattern.
Joseph’s activity is exclusively tied to Ionis Pharmaceuticals, indicating a concentrated focus on this single company. While the filings include transactions marked as "M" (derivative securities) and "A" (acquisitions), the majority of the value is derived from outright sales. The absence of recent purchases suggests a strategic reduction in his equity position in IONS. This pattern aligns with his broader trading history, which leans heavily toward liquidation rather than accumulation. The data reflects a deliberate and sustained effort to reduce his holdings in Ionis Pharmaceuticals, though the filings provide no insight into the underlying reasons for this trend.
AI-assisted summary